Apexigen is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer.
Recent advances in cancer immunology have increased our understanding of the mechanisms that cancer cells use to either avoid detection by or to de-activate the immune system. Novel immuno-oncology drugs are designed specifically to block immune suppression induced by tumors, or to actively initiate and augment an immune response against tumors. Manipulating the body’s immune system can lead to elimination of tumors and prevention of tumor recurrence (for a long-lasting cure).
Apexigen’s Immuno-oncology Strategy
Apexigen is focused on discovering and developing innovative drugs that enhance tumor-specific immunity. The use of its APXiMAB™ platform enables Apexigen to discover antibodies with unique attributes against known and novel immune system targets. These antibodies have demonstrated the potential to become the next generation of cancer therapies as we progress toward the ultimate cure for cancer.
April 12, 2022
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting 2022
April 7, 2022
Apexigen Announces That New Data From Phase 2 Trial Evaluating its CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma Will Be Presented at the AACR Annual Meeting 2022